证券日报网讯 8月1日晚间，长春高新发布公告称，截至2025年7月31日，公司累计通过回购专用证券账 户，以集中竞价交易方式累计回购公司股份3，894，517股，占本公司总股本的0.95%。 （文章来源：证券日报） ...

金融界消息 截至2025年8月1日收盘，长春高新（000661）报收于105.69元，上涨0.16%，换手率 1.95%，成交量7.78万手，成交金额8.32亿元。 天眼查商业履历信息显示，长春高新技术产业(集团)股份有限公司，成立于1993年，位于长春市，是一 家以从事医药制造业为主的企业。企业注册资本40793.7529万人民币，实缴资本3803.8477万人民币。公 司法定代表人为姜云涛。 通过天眼查大数据分析，长春高新技术产业(集团)股份有限公司共对外投资了26家企业，参与招投标项 目13次，知识产权方面有商标信息30条，此外企业还拥有行政许可6个。 来源：金融界 资金流向方面，今日主力资金净流入1420.73万元，占比成交额1.71%。其中，超大单净流入2171.43万 元、占成交额2.61%，大单净流出750.70万元、占成交额0.9%，中单净流出流入1374.95万元、占成交额 1.65%，小单净流出2795.68万元、占成交额3.36%。 长春高新最新一期业绩显示，截至2025一季报，公司营业总收入29.97亿元、同比减少5.66%，归属净利 润4.73亿元，同比减少44.95%，扣非净利润4 ...

根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引 第9号——回购股份》等相关法律法规的规定，公司在回购期间应当在每个月的 前三个交易日内公告截至上月末的回购进展情况。现将截至2025年7月31日的回 购股份进展情况公告如下： 一、回购进展情况 截至2025年7月31日，公司累计通过回购专用证券账户，以集中竞价交易方 式累计回购公司股份3,894,517股，占本公司总股本的0.95%，其中最高成交价为 112.25元/股，最低成交价为84.00元/股，合计成交金额为人民币399,999,400.76 元（含交易费用）。 证券代码：000661 证券简称：长春高新 公告编号：2025-069 长春高新技术产业（集团）股份有限公司 关于回购股份进展情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 长春高新技术产业（集团）股份有限公司（以下简称"公司"）于2024年 11月14日召开了第十一届董事会第六次会议，审议通过了《关于公司回购股份 方案的议案》，同意公司使用自有资金及金融机构股票回购专项贷款资金以集 中竞价交易方式回购部分公司已在境内 ...

Core Viewpoint - The assisted reproduction sector has shown a positive performance with a 1.72% increase, ranking third among concept sectors, driven by significant gains in several stocks [1][2]. Group 1: Sector Performance - As of July 31, the assisted reproduction concept increased by 1.72%, with 34 stocks rising, including Anke Bio and Gongtong Pharmaceutical, which both hit the 20% limit up [1]. - Notable gainers in the sector included Guangshengtang, Xinghao Pharmaceutical, and Hanyu Pharmaceutical, with increases of 18.04%, 8.03%, and 7.02% respectively [1]. - Conversely, stocks such as Jiabiyou, Changchun High-tech, and Zhejiang Medicine experienced declines of 3.70%, 3.02%, and 2.99% respectively [1]. Group 2: Capital Flow - The assisted reproduction sector saw a net inflow of 0.18 billion yuan, with 30 stocks receiving net inflows from major funds [2]. - Anke Bio led the sector with a net inflow of 4.09 billion yuan, followed by Zhongsheng Pharmaceutical and Hanshang Group with net inflows of 2.04 billion yuan and 1.44 billion yuan respectively [2]. - The top three stocks by net inflow ratio were Hanshang Group at 53.93%, Lideman at 35.62%, and Gongtong Pharmaceutical at 23.90% [3].

Core Viewpoint - Changchun High-tech has experienced a significant decline in stock price and market value, reflecting the challenges faced by the Chinese pharmaceutical industry as it transitions from reliance on "miracle drugs" to comprehensive innovation [1] Financial Performance - In 2024, Changchun High-tech reported its first revenue decline in nearly 20 years, with revenue of 13.466 billion yuan, a year-on-year decrease of 7.55%, and net profit of 2.708 billion yuan, down 43.01% [2] - The company's performance continued to deteriorate in Q1 2025, with net profit of 469 million yuan, a year-on-year decline of 47.36% [3] - From 2020 to 2023, the company's revenue grew from 8.577 billion yuan to 14.566 billion yuan, and net profit increased from 3.308 billion yuan to 4.776 billion yuan, but 2024 marked a turning point with revenue dropping to 13.466 billion yuan and net profit plummeting to 2.583 billion yuan, nearly a "halving" [4] Factors Contributing to Decline - The decline in performance is attributed to three main factors: centralized procurement policies, a decrease in birth rates, and price wars with competitors [5] - The inclusion of growth hormone in centralized procurement significantly impacted the company's core subsidiary, Jinsai Pharmaceutical, which contributed over 75% of revenue. The price of its main product dropped from approximately 1,000 yuan to 300 yuan, a reduction of 70%, leading to a 40.67% profit drop for Jinsai in 2024 [6] - The declining birth rate has reduced the potential user base for growth hormones, with newborn numbers dropping from 17.23 million in 2017 to 9.02 million in 2023 [6] Competitive Landscape - The long-acting growth hormone market, previously dominated by Jinsai, has seen increased competition with new entrants like Teva and Novo Nordisk, leading to a price war that further squeezed profit margins [7] - To capture market share, Changchun High-tech increased its sales team by 58% in 2024, raising sales expenses by 11.8% to 4.439 billion yuan [7] Employee Compensation and Workload - Despite the expansion of the sales team, average employee compensation decreased by approximately 15,000 yuan in 2024, reflecting increased workload and pressure on sales personnel [8][9] Vaccine Business Challenges - Changchun High-tech's subsidiary, Baike Biotechnology, faced significant challenges, with 2024 revenue dropping to 1.229 billion yuan, a year-on-year decline of 32.64%, and net profit halving to 232 million yuan [10] - The decline in demand for its shingles vaccine, which saw a 69.8% drop in sales volume, significantly impacted overall revenue [10] Innovation and Future Outlook - The company is attempting to explore new growth channels through its innovation pipeline, but it lags behind competitors in the number of clinical projects, with only 24 key products in clinical stages compared to over 300 by peers [11] - Key projects have faced delays, with the completion date for a significant product pushed back from June 2025 to June 2026, indicating challenges in maintaining a competitive edge [11]

Group 1 - Changchun High-tech announced that its subsidiary Brillian Pharma INC. received FDA approval for the oral solution of benidipine hydrochloride lyophilized powder, which is suitable for treating hypertension in patients aged 6 and above, as well as chronic stable angina and vasospastic angina in adults [1][2] - The approved product is a 505B2 modified innovative drug specifically designed for children over 6 years old and adults with swallowing difficulties, aimed at lowering blood pressure and reducing the risk of fatal and non-fatal cardiovascular events [1] - The product is developed based on existing FDA-approved original products, offering convenience in clinical use, accurate dosing, and palatable taste, enhancing medication adherence for pediatric patients [1] Group 2 - The approval of this product will enrich Brillian Pharma's product portfolio in the U.S. market and enhance the company's competitiveness in the pharmaceutical sector [2] - The company plans to actively organize market promotion, production, and sales efforts to facilitate the widespread application of the product, providing more treatment options for patients [2]

金融界消息 截至2025年7月30日收盘，长春高新（000661）报收于108.81元，上涨2.76%，换手率 3.61%，成交量14.44万手，成交金额15.66亿元。 资金流向方面，今日主力资金净流入5351.00万元，占比成交额3.42%。其中，超大单净流入1.15亿元、 占成交额7.37%，大单净流出6192.57万元、占成交额3.95%，中单净流出流出176.80万元、占成交额 0.11%，小单净流出5174.20万元、占成交额3.3%。 通过天眼查大数据分析，长春高新技术产业(集团)股份有限公司共对外投资了26家企业，参与招投标项 目13次，知识产权方面有商标信息30条，此外企业还拥有行政许可6个。 来源：金融界 天眼查商业履历信息显示，长春高新技术产业(集团)股份有限公司，成立于1993年，位于长春市，是一 家以从事医药制造业为主的企业。企业注册资本40793.7529万人民币，实缴资本3803.8477万人民币。公 司法定代表人为姜云涛。 长春高新最新一期业绩显示，截至2025一季报，公司营业总收入29.97亿元、同比减少5.66%，归属净利 润4.73亿元，同比减少44.95%，扣非净利润4 ...

Group 1 - Novo Nordisk has lowered its full-year financial guidance for 2025, expecting sales growth of 8% to 14% at constant exchange rates, down from a previous forecast of 13% to 21% [1] - The downward revision is attributed to lower growth expectations for Wegovy in the U.S. obesity market and Ozempic in the U.S. GLP-1 diabetes market, as well as lower-than-expected penetration rates for Wegovy in some international markets [1] - This reflects a trend of rational return in the GLP-1 sector, indicating that even leading companies face challenges in sustaining high-speed expansion amid high bases and intense market competition [1] Group 2 - Enhua Pharmaceutical reported a net profit of approximately 700 million yuan for the first half of 2025, an increase of 11.38% year-on-year, with total revenue reaching 3.01 billion yuan, up 8.93% [2][3] - The company demonstrated steady performance in the pain relief and anesthetic sectors, maintaining a solid market position despite overall pressures in the pharmaceutical industry [2] Group 3 - Changchun High-tech's subsidiary has received FDA approval for its innovative drug, Amlodipine Besylate Oral Solution Lyophilized Powder, aimed at treating hypertension in children over 6 years old and adults with swallowing difficulties [3] - This approval enhances the company's product portfolio in the U.S. market and strengthens its competitive position in the pharmaceutical sector [3] - The product is a modified innovative drug that reduces blood pressure and minimizes the risk of cardiovascular events [3] Group 4 - Zhixiang Jintai has received clinical trial approval for its investigational product, SLEWEMI Monoclonal Antibody Injection, for passive immunity in children and adolescents exposed to suspected rabies virus [3] - This product is the world's first dual-specific antibody for rabies passive immunity, developed in accordance with WHO recommendations for antibody development [3] - The approval highlights the company's capabilities in international registration and the development of modified drugs [3]

Macro News - The International Monetary Fund (IMF) has significantly raised China's economic growth forecast for this year by 0.8 percentage points to 4.8%, reflecting stronger-than-expected economic activity in the first half of the year and lower actual tariff rates compared to previous predictions [4] - In the first half of the year, state-owned enterprises in China reported total operating revenue of 4,074.96 billion yuan, a year-on-year decrease of 0.2%. Their total profit amounted to 218.25 billion yuan, down 3.1% year-on-year, and tax payments were 300.26 billion yuan, a decline of 0.8% [4] Industry News - Hong Kong's "Stablecoin Regulation" will come into effect on August 1, with the Hong Kong Monetary Authority releasing five regulatory documents for licensed stablecoin issuers [7] - The China Photovoltaic Industry Association issued a statement refuting claims made by some media regarding "anti-involution" in the photovoltaic industry, particularly concerning polysilicon, stating that the reports were severely inconsistent with actual conditions [7] Company News - WuXi AppTec announced an adjustment to its share repurchase price ceiling to no more than 114.15 yuan per share [11] - The PCB industry is experiencing a significant improvement in market conditions compared to the same period last year, especially for high-end products, with strong demand and rising prices [9] - Changchun High-tech announced that its innovative drug, Amlodipine Besylate Oral Solution, has received approval from the FDA for market launch in the United States [12]

Core Viewpoint - Changchun High-tech has received FDA approval for its subsidiary Brillian Pharma INC.'s formulation of Amlodipine Besylate oral solution, targeting hypertension in children aged 6 and above and adults, enhancing the company's product portfolio in the U.S. market [1][2] Group 1: Product Approval and Indications - The FDA has approved the Amlodipine Besylate oral solution for treating hypertension in individuals aged 6 and older, as well as chronic stable angina and vasospastic angina in adults [1] - Hypertension affects 47.7% of U.S. adults aged 18 and older, and 3.8% of children aged 6-17, highlighting a significant market need for effective treatments [1] Group 2: Product Features and Benefits - The Amlodipine Besylate oral solution is a 505B2 modified innovative drug designed for children and adults with swallowing difficulties, aimed at reducing blood pressure and cardiovascular event risks [2] - The product is developed based on existing FDA-approved formulations, ensuring ease of use, accurate dosing, and palatable taste, which enhances adherence among pediatric patients [2] - The formulation can be stored at room temperature without the need for cold chain logistics, ensuring safety and accuracy in clinical use [2] Group 3: Market Strategy and Outlook - The approval of this product is expected to enrich Brillian Pharma's product offerings in the U.S. market and strengthen the company's competitive position in the pharmaceutical sector [2] - The company plans to actively promote, produce, and sell the product, aiming for widespread market application and providing more treatment options for patients [2]